CORRECTION article

Front. Oncol., 19 June 2025

Sec. Hematologic Malignancies

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1641150

Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study

  • 1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

  • 2. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China

Article metrics

View details

1,3k

Views

312

Downloads

In the published article, there was an error in the Funding statement. “The funder National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan” was erroneously omitted. The correct Funding statement appears below.

“This study was supported by the National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan. This study also received funding from Xiamen Amoytop Biotech Co., Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

polycythemia vera, pegylated interferon, JAK2v617F mutation, dose de-escalation strategy, hematological and molecular response

Citation

Chang L, Li W-X, Cai H, Li J and Duan M-H (2025) Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. Front. Oncol. 15:1641150. doi: 10.3389/fonc.2025.1641150

Received

04 June 2025

Accepted

06 June 2025

Published

19 June 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2025

Updates

Copyright

*Correspondence: Ming-Hui Duan,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics